Navigation Links
Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
Date:11/23/2008

CARLSBAD, Calif., Nov. 23 /PRNewswire/ -- Essentialis Inc, a clinical stage pharmaceutical company, announced today that it has completed enrollment in a 92-patient Phase 2 trial of DCCR in dyslipidemic patients. The study encompasses both patients with very high triglycerides and mixed dyslipidemia and includes normal weight, overweight and obese patients presenting with or without hypertension.

The randomized, double-blind study is designed to assess the drug's effect on dyslipidemia and will evaluate three different doses of DCCR given over an 8-week period. Randomization was stratified by Body Mass Index (BMI) and concurrent use of statin drugs. The endpoints of the study include measurements of the effect of treatment on triglycerides, total-cholesterol, LDL-cholesterol, HDL-cholesterol and non-HDL-cholesterol, compared to placebo. The effects of DCCR on body weight, blood pressure and liver function tests compared to placebo are also being assessed. A total of 16 patients have completed the study, and an additional 20 have completed the double-blind treatment phase. The last patient last visit is scheduled for January 30th, 2009. Top-line results are anticipated in late March, 2009.

Commenting on this milestone achievement, Essentialis President and CEO, Iain Dukes said, "Essentialis is now closer to understanding the ability of DCCR to treat both very high triglycerides and mixed dyslipidemia, delivering a competitive profile of across the board lipid improvements with the added potential benefit of weight loss."

About DCCR

DCCR, diazoxide choline controlled release, is an ATP-dependent potassium channel agonist with potential utility in several cardiovascular and metabolic diseases. Extensive Phase 1 testing and investigator-sponsored clinical studies have demonstrated the drug's potential to lower triglycerides, non-HDL cholesterol and LDL-cholesterol while raising HDL-cholest
'/>"/>

SOURCE Essentialis Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
2. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
3. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
4. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
10. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
(Date:7/30/2015)... Inc. (NYSE: RMD ) today announced results for ... quarter was $453.1 million, a 9 percent increase compared ... percent increase on a constant currency basis).  Net income ... 30, 2014.  Diluted earnings per share for the quarter ... 2014.  The results for the quarter ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... new white paper urges medical device and combination product ... as a means of preventing the failure of ... medical products are based on years of data that ... occur due to inadequate package validation programs," said Steven ...
... 16, 2010 Reportlinker.com announces that a new ... Global Analgesics Industry ... the worldwide markets for Analgesics in US$ Million ... Ibuprofen, and Others (includes combination drugs)), and External ...
Cached Medicine Technology:New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products 2New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products 3Reportlinker Adds Global Analgesics Industry 2Reportlinker Adds Global Analgesics Industry 3Reportlinker Adds Global Analgesics Industry 4Reportlinker Adds Global Analgesics Industry 5Reportlinker Adds Global Analgesics Industry 6Reportlinker Adds Global Analgesics Industry 7Reportlinker Adds Global Analgesics Industry 8Reportlinker Adds Global Analgesics Industry 9Reportlinker Adds Global Analgesics Industry 10Reportlinker Adds Global Analgesics Industry 11Reportlinker Adds Global Analgesics Industry 12Reportlinker Adds Global Analgesics Industry 13Reportlinker Adds Global Analgesics Industry 14Reportlinker Adds Global Analgesics Industry 15Reportlinker Adds Global Analgesics Industry 16Reportlinker Adds Global Analgesics Industry 17Reportlinker Adds Global Analgesics Industry 18Reportlinker Adds Global Analgesics Industry 19Reportlinker Adds Global Analgesics Industry 20Reportlinker Adds Global Analgesics Industry 21
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of the network ... their Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been ... companies have agreed to join their missions of purpose together to change the course ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... Lume Wellness ... that is free to download on the Apple AppStore. , The app is ... even mood, thus acting as a tool to view personal health and use this ...
(Date:8/1/2015)... ... 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked ... and was greeted by friends and family. He visited CCAR and left an inspirational ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source for ... Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... for the annual Lollapalooza. This unique and unbelievably popular festival attracts the best ...
Breaking Medicine News(10 mins):Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2
... 20 Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: ... its epigenetic technology successfully inhibits tumor growth.The results ... at the 100th Annual American Association for Cancer ... in ,switching on, important anti-cancer genes - a ...
... April 20 A new alliance between the ... leading manufacturer of unattended massage beds is focused ... a new and affordable service to customers.(Photo: ... Enterprises manufactures the HydroMassage, a massage system that ...
... the University of Southern California have identified a new ... surrounding blood vessels without the negative side effects typically ... 2.5-dimethyl-celecoxib (DMC) appears to have a strong anti-tumor effect ... supply necessary for tumor growth, according to data presented ...
... Fluorescent Channels to Enable Greater Data Ranges and Multiplexing ... Series Launched to Enable Imaging, Co-Registration and Data Fusion ... April 20 VisEn Medical Inc., a ... research through medicine, announced that users of its FMT ...
... added everolimus (Afinitor(R), Novartis) to the NCCN Guidelines for ... renal cell carcinoma whose disease has progressed after treatment ... of the March 30, 2009 FDA approval of everolimus ... that the therapy significantly extended progression-free survival in a ...
... Schwabe North America , has announced the ... Way sales teams. The integration marks an exciting ... Inc. by German-based Dr. Willmar Schwabe Pharmaceuticals, a leading ... years.The combined Specialty Retail Field Sales Team will service ...
Cached Medicine News:Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 2Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 3Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 4Health News:ETS Tan Now Exclusive Distributor of HydroMassage in U.S. 2Health News:USC researchers develop new drug to target tumor cells and blood vessels 2Health News:VisEn Medical Launches Expanded FMT 2500(TM) Imaging Platforms at AACR Meeting 2Health News:VisEn Medical Launches Expanded FMT 2500(TM) Imaging Platforms at AACR Meeting 3Health News:NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus 2Health News:NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus 3Health News:Schwabe North America Integrates Enzymatic Therapy and Nature's Way Sales Teams 2
For regulating sample flow rate when using the QIAvac 24 Plus;...
Holder for QIAGEN 96-well plates, for use with QIAvac 96;...
For connecting the QIAvac 24 Plus and Vacuum Pump;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
Medicine Products: